Skip to main content
Premium Trial:

Request an Annual Quote

A Personal Effort

Stanford University's Ron Davis has become focused on helping people with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), CNN reports. It writes that the work is personal for him, as his son has a severe form of the condition and needs the care of Davis and his wife, Janet Dafoe.

"It has turned my life upside down in many respects. I decided to terminate everything I was working on before Whitney got sick," Davis tells CNN. "Everything is ME/CFS now. It's an emergency kind of effort."

The Open Medicine Foundation — Davis directs its scientific advisory board — committed $1.2 million toward a ME/CFS Collaborative Research Center at Stanford in 2017, as GenomeWeb reported at the time. CNN adds that OMF has raised $18 million to study the disease. It further notes that Davis and his colleagues are analyzing blood from Davis' son and other patients using a nanoneedle they developed. They hope, it says, to tease out a biomarker for the disease, which they say would help the condition be better recognized and help drug companies develop treatments.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.